Medical marijuana: Review of the science and implications for developmental-behavioral pediatric practice

Journal of Developmental and Behavioral Pediatrics

Volumn 36, Issue 2, 2015, Pages 115-123

  Hadland, Scott E ^a,b   Knight, John R ^a   Harris, Sion K ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adolescent; attention deficit disorder with hyperactivity; cannabis; child development disorders; marijuana abuse; pervasive

Indexed keywords

CANNABIS; MEDICAL CANNABIS;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANIMAL; CHILD; DRUG EFFECTS; HUMAN; NEURODEVELOPMENTAL DISORDERS;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANIMALS; CANNABIS; CHILD; HUMANS; MEDICAL MARIJUANA; NEURODEVELOPMENTAL DISORDERS;

EID: 84923148941     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0000000000000129     Document Type: Review

References (91)

1. GCODP. War on Drugs: Report of the Global Commission on Drug Policy. 2011. Available at: http://www.globalcommissionon drugs.org/wp-content/themes/gcdp-v1/pdf/Global-Commission -Report-English.pdf. Accessed 6 October, 2013.
2. Kilmer B, Caulkins JP, Pacula RL, et al. Drug Policy Landscape: Insights and Opportunities for Improving the View. 2012. Available at: http://www.rand.org/pubs/occasional-papers/OP393. html. Accessed March 26, 2014.
3. Richter KP, Levy S. Big marijuana-lessons from big tobacco. N Engl J Med. 2014;371:399-401.
4. Reinarman C, Cohen PD, Kaal HL. The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco. Am J Public Health. 2004;94:836-842.
5. Lynne-Landsman SD, Livingston MD, Wagenaar AC. Effects of state medical marijuana laws on adolescent marijuana use. Am J Public Health. 2013;103:1500-1506.
6. Arie S. Uruguay legalises sale and production of marijuana. BMJ. 2013;347:f7499.
7. Levy S. Effects of marijuana policy on children and adolescents. JAMA Pediatr. 2013;167:600-602.
8. Miles K. Marijuana-like Chemical may help Autism and Fragile X Syndrome Symptoms. 2012. Available at: http://www. huffingtonpost.com/2012/09/27/marijuana-chemical-autism-fragilex- n-1920320.html. Accessed March 26, 2014.
9. Ellison K. Medical Marijuana: No Longer Just for Adults. 2009. Available at: http://www.nytimes. com/2009/11/22/health/22sfmedical.html. Accessed March 26, 2014.
10. Young S. Marijuana Stops Child's Severe Seizures. 2013. Available at: http://www.cnn.com/2013/08/07/health/charlotte-child-medical- marijuana/. Accessed March 26, 2014.
11. Ferner M. Number of Children Seeking Medical Marijuana Soars in Colorado. 2014. Available at: http://www.huffingtonpost. com/2014/02/13/medical-marijuana-children-n-4768219.html. Accessed April 16, 2014.
12. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82: 1556-1563.
13. Porter BE, Jacobson C. Report of a parent survey of cannabidiolenriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574-577.
14. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.
15. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2011. MMWR Surveill Summ. 2012;61: 1-162.
16. Johnston LD, O'Mally PM, Bachman JG, et al. Monitoring the Future National Results on Drug Use: 2013 Overview, Key Findings on Adolescent Drug Use. 2013. Available at: http://www. monitoringthefuture.org/data/13data.html. Accessed 30 December, 2013.
17. SAMHSA. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. 2013. Available at: http: //www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/ NationalFindings/NSDUHresults2012.htm. Accessed 19 September, 2013.
18. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:1383-1391.
19. Joffe A. Legalization of marijuana: potential impact on youth. Pediatrics. 2004;113:1825-1826.
20. AMA. H-95.998 AMA Policy Statement on Cannabis (Marijuana). 2012. Available at: http://www.ama-assn. org/resources/doc/PolicyFinder/policyfiles/HnE/H-95.998.htm. Accessed 24 January, 2014.
21. ASAM. Public Policy Statement on Marijuana. 2006. Available at: http://www.asam.org/docs/publicy-policy-statements/1marijuana- 5-062.pdf. Accessed 24 January, 2014.
22. ASAM. White Paper on State-Level Proposals to Legalize Marijuana. 2012. Available at: http://www.asam. org/docs/publicy-policy-statements/state-level-proposals-to-legalize-marijuana- final2773DD668C2D.pdf. Accessed 24 January, 2014.
23. AACAP. AACAP Medical Marijuana Policy Statement. 2012. Available at: http://www.aacap.org/AACAP/Policy-Statements/ 2012/AACAP-Medical-Marijuana-Policy-Statement.aspx. Accessed 24 January, 2014.
24. Abrams DI, Vizoso HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007; 82:572-578.
25. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of delta9- THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55:1209-1217.
26. Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ. 2010;340:c1571.
27. Bramness JG, Khiabani HZ, Morland J. Impairment due to cannabis and ethanol: clinical signs and additive effects. Addiction. 2010; 105:1080-1087.
28. Harkany T, Guzmán M, Hurd YL. Endocannabinoid functions in neurogenesis, neuronal migration, and specification. In: Köfalvi A, ed. Cannabinoids and the Brain. New York, NY: Springer Science 1 Business Media, LLC; 2008:237-256.
29. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327-360.
30. Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol. 2008;21:494-502.
31. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22:325-336.
32. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol. 2011;6:459-480.
33. Sacco LN, Finklea K. Synthetic Drugs: Overview and Issues for Congress. 2013. Available at: https://www.fas. org/sgp/crs/misc/R42066.pdf. Accessed 7 October, 2013.
34. UNODC. World Drug Report 2013. 2013. Available at: http://www. unodc.org/unodc/secured/wdr/wdr2013/World-Drug-Report-2013. pdf. Accessed 7 October, 2013.
35. Substance Abuse and Mental Health Services Administration, Center for Behavioral Statistics and Quality. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Available at: http://www.samhsa.gov/data/2k13/DAWN127/sr127- DAWN-highlights.htm. Accessed September 3, 2014.
36. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 2013;167:630-633.
37. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med. 2014;63:684-689.
38. Creemers HE, van Lier PA, Vollebergh WA, et al. Predicting onset of cannabis use in early adolescence: the interrelation between highintensity pleasure and disruptive behavior. The TRAILS study. J Stud Alcohol Drugs. 2009;70:850-858.
39. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict. 1997;6:205-217.
40. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112:497-507.
41. Charach A, Yeung E, Climans T, et al. Childhood attention-deficit/ disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9-21.
42. Groenman AP, Oosterlaan J, Rommelse N, et al. Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study. Addiction. 2013;108:1503-1511.
43. Elkins IJ, McGue M, Iacono WG. Prospective effects of attentiondeficit/ hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry. 2007; 64:1145-1152.
44. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003; 111:179-185.
45. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70:740-749.
46. De Alwis D, Agrawal A, Reiersen AM, et al. ADHD symptoms, autistic traits, and substance use and misuse in adult Australian twins. J Stud Alcohol Drugs. 2014;75:211-221.
47. Carroll Chapman SL, Wu LT. Substance abuse among individuals with intellectual disabilities. Res Dev Disabil. 2012;33:1147-1156.
48. Chaplin E, Gilvarry C, Tsakanikos E. Recreational substance use patterns and co-morbid psychopathology in adults with intellectual disability. Res Dev Disabil. 2011;32:2981-2986.
49. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014;6:39-45.
50. Hadland SE, Kerr T, Li K, et al. Access to drug and alcohol treatment among a cohort of street-involved youth. Drug Alcohol Depend. 2009;101:1-7.
51. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371:879.
52. Lisdahl KM, Gilbart ER, Wright NE, et al. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53.
53. Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict. 2007;16(suppl 1): 14-21; quiz 22-13.
54. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1-8.
55. Medina KL, Hanson KL, Schweinsburg AD, et al. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc. 2007;13: 807-820.
56. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344:e536.
57. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98:1089-1095.
58. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry. 2006;15:105-125.
59. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attentiondeficit/ hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry. 2000;61:244-251.
60. SADD LM. Hazy Logic: Liberty Mutual Insurance/SADD Study Finds Driving Under the Influence of Marijuana a Greater Threat to Teen Drivers than Alcohol. 2012. Available at: http: //www.sadd.org/press/presspdfs/MarijuanaTeenRelease.pdf. Accessed 30 Dec, 2013.
61. Whitehill JM, Rivara FP, Moreno MA. Marijuana-using drivers, alcohol-using drivers, and their passengers: prevalence and risk factors among underage college students. JAMA Pediatr. 2014;168: 618-624.
62. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109:E2657-E2664.
63. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
64. Manrique-Garcia E, Zammit S, Dalman C, et al. Cannabis, schizophrenia and other non-affective psychoses: 35 years of followup of a population-based cohort. Psychol Med. 2012;42:1321-1328.
65. Horwood LJ, Fergusson DM, Coffey C, et al. Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend. 2012;126:369-378.
66. Rasic D, Weerasinghe S, Asbridge M, et al. Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school students. Drug Alcohol Depend. 2013;129:49-53.
67. Degenhardt L, Coffey C, Romaniuk H, et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013;108:124-133.
68. Galve-Roperh I, Palazuelos J, Aguado T, et al. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2009;259:371-382.
69. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13: 253-263.
70. Busquets-Garcia A, Maldonado R, Ozaita A. New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model. Int J Biochem Cell Biol. 2014; 53:121-126.
71. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med. 2013;19:603-607.
72. Jung KM, Sepers M, Henstridge CM, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080.
73. Zalesky A, Solowij N, Yucel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135:2245-2255.
74. Schacht JP, Hutchison KE, Filbey FM. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology. 2012;37:2368-2376.
75. Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014;39: 2041-2048.
76. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1-25.
77. Mothers for Medical Marijuana Treatment for Autism. Available at: https://www.facebook.com/pages/Mothers-for-medical-marijuana-treatment-for-autism/236681176392778. Accessed March 30, 2014.
78. MAMMA-Mothers Advocating Medical Marijuana for Autism. Available at: https://www.facebook.com/TexasMammas. Accessed March 30, 2014.
79. Pediatric Cannabis Therapy. Available at: https://www.facebook. com/groups/151947154925108/. Accessed March 30, 2014.
80. Foldy C, Malenka RC, Sudhof TC. Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling. Neuron. 2013;78:498-509.
81. Adams M. Marijuana May be Used to Treat Autism. 2013. Available at: http://www.hightimes.com/read/marijuana-may-be-used-treat-autism. Accessed March 26, 2014.
82. Grush L. Marijuana-Like Brain Chemicals Could be Key to Treating Fragile X Syndrome. 2012. Available at: http://www.foxnews. com/health/2012/09/25/marijuana-like-brain-chemicals-could-be-key-to- treating-fragile-x-syndrome/. Accessed March 31, 2014.
83. Kurz R, Blaas K. Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids. 2010;5:4-6.
84. Strohbeck-Kuehner P, Skopp G, Mattern R. Cannabis improves symptoms of ADHD. Cannabinoids. 2008;3:1-3.
85. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161:1967-1977.
86. Kruger T, Christophersen E. An open label study of the use of dronabinol (Marinol) in the management of treatment-resistant selfinjurious behavior in 10 retarded adolescent patients. J Dev Behav Pediatr. 2006;27:433.
87. Cannabis Science and The Unconventional Foundation for Autism (UF4A) Partner to Advance Successful Cannabis-based Autism Treatments. 2011. Available at: http://www.reuters.com/article/2011/ 03/17/idUS143853117-Mar-20111BW20110317. Accessed March 30, 2014.
88. Cannabis Science, Inc. (CBIS) Announces Submission of Cannabinoid-Based Patent Application N2010968 Titled "Composition for the Treatment of Neurobehavioral disorders". 2013. Available at: http://www.cannabisscience.com/index.php/newsmedia/ news-releases/321-cannabis-science-inc-cbis-announces-submission- of-cannabinoid-based-patent-application-n2010968-titled-composition- for-the-treatment-of-neurobehavioral-disorders. Accessed March 30, 2014.
89. Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana- polling results. N Engl J Med. 2013;368:e30.
90. Bostwick JM, Reisfield GM, DuPont RL. Clinical decisions. Medicinal use of marijuana. N Engl J Med. 2013;368:866-868.
91. Turcotte D, Le Dorze JA, Esfahani F, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother. 2010;11: 17-31.